Share Price and Basic Stock Data
Last Updated: December 30, 2025, 8:37 pm
| PEG Ratio | -0.35 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Dipna Pharmachem Ltd operates in the pharmaceuticals sector, with its stock price currently standing at ₹16.9 and a market capitalization of ₹44.4 Cr. The company has demonstrated a significant upward trend in revenue, with sales increasing from ₹17 Cr in March 2018 to ₹100 Cr in March 2023, peaking at ₹164 Cr in March 2024. The trailing twelve months (TTM) revenue is reported at ₹108 Cr, indicating a robust performance. Quarterly sales have also shown resilience, with ₹74 Cr reported in both September 2023 and March 2024, suggesting stable demand. However, the revenue dipped to ₹34 Cr in March 2025, highlighting potential volatility. The operating profit margin (OPM) has fluctuated, recorded at 4% currently, reflecting the challenges in managing operational costs relative to sales. Overall, the revenue trends illustrate a growth trajectory but reveal risks related to sales fluctuations and cost management.
Profitability and Efficiency Metrics
Dipna Pharmachem Ltd has recorded a net profit of ₹2 Cr, translating to a return on equity (ROE) of 2.55% and a return on capital employed (ROCE) of 6.64%. The company’s profitability has been inconsistent, with a net profit margin currently at 0.77%, which is low compared to industry standards. The operating profit has shown modest growth, reaching ₹4 Cr in March 2025, up from ₹2 Cr in the previous year, indicating improved operational efficiency. However, the OPM has remained relatively low at around 2-3% over the last few years, suggesting that while revenue has increased, cost control remains a significant challenge. The cash conversion cycle (CCC) has notably improved, standing at -20 days, reflecting efficient management of working capital. This efficiency, combined with a steady increase in operating profits, presents a positive outlook for the company’s future profitability.
Balance Sheet Strength and Financial Ratios
Dipna Pharmachem Ltd’s balance sheet shows total assets of ₹177 Cr against total liabilities of ₹132 Cr, indicating a sound asset base. The company’s equity capital has increased to ₹24 Cr, while reserves have risen significantly to ₹35 Cr, reflecting a strengthening financial position. Borrowings are reported at ₹14 Cr, demonstrating a manageable debt level with a debt-to-equity ratio of 0.44x. The interest coverage ratio (ICR) is at 1.71x, suggesting that the company can comfortably meet its interest obligations. However, the price-to-book value (P/BV) ratio stands at 0.89x, indicating that the stock may be undervalued compared to its book value. Additionally, the current ratio is 1.56x, which is above the typical industry benchmark, suggesting good short-term financial health. Overall, the balance sheet reflects a stable financial structure with manageable debt levels, though the low ROE remains a concern for investors.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Dipna Pharmachem Ltd has undergone significant changes, with promoter holdings declining from 66.56% in September 2022 to 9.13% as of November 2025. Conversely, public shareholding has increased from 33.45% to 90.87% during the same period, indicating a shift towards greater public ownership and potentially enhanced liquidity. The number of shareholders has fluctuated, peaking at 2,652 in September 2024 before settling at 1,741 in November 2025. This transition from concentrated promoter ownership to a more diversified public base could reflect growing investor confidence in the company’s future prospects. However, the sharp decline in promoter stakes may raise concerns regarding the long-term commitment of the founding management. Overall, the current distribution suggests a more democratic ownership structure that may attract institutional investors in the future.
Outlook, Risks, and Final Insight
The outlook for Dipna Pharmachem Ltd appears cautiously optimistic, driven by revenue growth and improved operational efficiency. However, risks remain, particularly in maintaining profitability amid fluctuating sales and low profit margins. The volatility seen in quarterly sales, particularly the dip to ₹34 Cr in March 2025, raises concerns about market stability and demand consistency. Additionally, the drastic reduction in promoter ownership may impact strategic decision-making and investor sentiment. On the other hand, the company’s solid balance sheet, with manageable debt and increasing reserves, provides a foundation for future growth. If management can navigate the challenges of cost control and stabilize sales, there is potential for improved profitability and shareholder value. The shift towards greater public ownership could also lead to increased scrutiny and accountability, which may benefit the company in the long run.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 129 Cr. | 103 | 231/84.3 | 28.6 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,816 Cr. | 442 | 479/192 | 99.7 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.3 Cr. | 43.5 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 52.4 Cr. | 35.8 | 36.4/17.0 | 125 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,197.40 Cr | 1,153.64 | 53.52 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 29 | 44 | 49 | 74 | 74 | 90 | 91 | 34 | 74 |
| Expenses | 28 | 42 | 48 | 73 | 73 | 88 | 89 | 32 | 71 |
| Operating Profit | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 2 | 3 |
| OPM % | 3% | 3% | 2% | 2% | 2% | 2% | 2% | 6% | 4% |
| Other Income | -0 | 0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Interest | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | -0 | -0 | -0 | 0 | 0 | 0 | -0 | 0 | 0 |
| Profit before tax | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 2 |
| Tax % | 25% | 26% | 26% | 27% | 27% | 21% | 26% | 34% | 26% |
| Net Profit | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 |
| EPS in Rs | 33.00 | 84.00 | 0.13 | 0.24 | 0.24 | 0.20 | 0.14 | 0.27 | 0.59 |
Last Updated: December 27, 2025, 6:03 am
Below is a detailed analysis of the quarterly data for Dipna Pharmachem Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 74.00 Cr.. The value appears strong and on an upward trend. It has increased from 34.00 Cr. (Mar 2025) to 74.00 Cr., marking an increase of 40.00 Cr..
- For Expenses, as of Sep 2025, the value is 71.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 32.00 Cr. (Mar 2025) to 71.00 Cr., marking an increase of 39.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 3.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2025) to 3.00 Cr., marking an increase of 1.00 Cr..
- For OPM %, as of Sep 2025, the value is 4.00%. The value appears to be declining and may need further review. It has decreased from 6.00% (Mar 2025) to 4.00%, marking a decrease of 2.00%.
- For Other Income, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Interest, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Mar 2025) to 2.00 Cr., marking an increase of 1.00 Cr..
- For Tax %, as of Sep 2025, the value is 26.00%. The value appears to be improving (decreasing) as expected. It has decreased from 34.00% (Mar 2025) to 26.00%, marking a decrease of 8.00%.
- For Net Profit, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.59. The value appears strong and on an upward trend. It has increased from 0.27 (Mar 2025) to 0.59, marking an increase of 0.32.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:50 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 17 | 20 | 30 | 31 | 73 | 100 | 164 | 125 | 108 |
| Expenses | 16 | 20 | 30 | 31 | 71 | 98 | 161 | 121 | 103 |
| Operating Profit | 0 | 0 | 0 | 0 | 2 | 2 | 3 | 4 | 5 |
| OPM % | 2% | 2% | 1% | 1% | 3% | 2% | 2% | 3% | 5% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 1 | 3 |
| Tax % | 14% | 40% | 0% | 60% | 26% | 34% | 24% | 32% | |
| Net Profit | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 |
| EPS in Rs | 6.00 | 3.00 | 6.00 | 2.00 | 117.00 | 0.37 | 0.45 | 0.40 | 0.86 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 0.00% | 0.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 0.00% | 0.00% |
Dipna Pharmachem Ltd has shown a consistent positive trend in YoY Net Profit Growth (%) in the last 3 years from 2022-2023 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 33% |
| 3 Years: | 20% |
| TTM: | -24% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 74% |
| 3 Years: | -6% |
| TTM: | -11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 142% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 5% |
| 3 Years: | 4% |
| Last Year: | 3% |
Last Updated: September 5, 2025, 3:16 pm
Balance Sheet
Last Updated: December 4, 2025, 2:45 am
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 12 | 24 | 24 | 24 |
| Reserves | 0 | 0 | 1 | 1 | 2 | 12 | 13 | 14 | 35 |
| Borrowings | 5 | 6 | 10 | 12 | 10 | 16 | 19 | 17 | 14 |
| Other Liabilities | 6 | 8 | 8 | 12 | 24 | 37 | 76 | 77 | 105 |
| Total Liabilities | 11 | 14 | 18 | 25 | 36 | 78 | 133 | 132 | 177 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 11 | 14 | 18 | 25 | 36 | 78 | 133 | 132 | 177 |
| Total Assets | 11 | 14 | 18 | 25 | 36 | 78 | 133 | 132 | 177 |
Below is a detailed analysis of the balance sheet data for Dipna Pharmachem Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 24.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 24.00 Cr..
- For Reserves, as of Sep 2025, the value is 35.00 Cr.. The value appears strong and on an upward trend. It has increased from 14.00 Cr. (Mar 2025) to 35.00 Cr., marking an increase of 21.00 Cr..
- For Borrowings, as of Sep 2025, the value is 14.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 17.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 3.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 105.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 77.00 Cr. (Mar 2025) to 105.00 Cr., marking an increase of 28.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 177.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 132.00 Cr. (Mar 2025) to 177.00 Cr., marking an increase of 45.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 177.00 Cr.. The value appears strong and on an upward trend. It has increased from 132.00 Cr. (Mar 2025) to 177.00 Cr., marking an increase of 45.00 Cr..
- For Total Assets, as of Sep 2025, the value is 177.00 Cr.. The value appears strong and on an upward trend. It has increased from 132.00 Cr. (Mar 2025) to 177.00 Cr., marking an increase of 45.00 Cr..
Notably, the Reserves (35.00 Cr.) exceed the Borrowings (14.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -5.00 | -6.00 | -10.00 | -12.00 | -8.00 | -14.00 | -16.00 | -13.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 132 | 160 | 134 | 176 | 135 | 104 | 69 | 135 |
| Inventory Days | 112 | 66 | 70 | 89 | 34 | 72 | 86 | 88 |
| Days Payable | 142 | 148 | 105 | 145 | 123 | 139 | 172 | 243 |
| Cash Conversion Cycle | 103 | 78 | 99 | 120 | 46 | 38 | -17 | -20 |
| Working Capital Days | 3 | 6 | 44 | 47 | 37 | 108 | 80 | 137 |
| ROCE % | 8% | 5% | 3% | 17% | 9% | 7% | 7% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.41 | 0.45 | 260.55 | 333.40 | 6.91 |
| Diluted EPS (Rs.) | 0.41 | 0.45 | 260.55 | 333.40 | 6.91 |
| Cash EPS (Rs.) | 0.40 | 0.45 | 0.77 | 335.17 | 8.97 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 16.01 | 15.60 | 20.35 | 496.74 | 163.34 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 16.01 | 15.60 | 20.35 | 496.74 | 163.34 |
| Revenue From Operations / Share (Rs.) | 51.95 | 68.34 | 83.48 | 20787.26 | 8857.11 |
| PBDIT / Share (Rs.) | 1.43 | 1.43 | 1.96 | 644.23 | 118.66 |
| PBIT / Share (Rs.) | 1.43 | 1.42 | 1.95 | 642.46 | 116.60 |
| PBT / Share (Rs.) | 0.59 | 0.59 | 1.15 | 449.80 | 15.71 |
| Net Profit / Share (Rs.) | 0.40 | 0.45 | 0.76 | 333.40 | 6.91 |
| PBDIT Margin (%) | 2.75 | 2.08 | 2.35 | 3.09 | 1.33 |
| PBIT Margin (%) | 2.75 | 2.07 | 2.33 | 3.09 | 1.31 |
| PBT Margin (%) | 1.13 | 0.86 | 1.38 | 2.16 | 0.17 |
| Net Profit Margin (%) | 0.77 | 0.66 | 0.91 | 1.60 | 0.07 |
| Return on Networth / Equity (%) | 2.53 | 2.89 | 3.74 | 67.11 | 4.23 |
| Return on Capital Employeed (%) | 7.25 | 6.82 | 6.06 | 44.39 | 9.58 |
| Return On Assets (%) | 0.73 | 0.81 | 1.17 | 3.22 | 0.09 |
| Long Term Debt / Equity (X) | 0.23 | 0.33 | 0.58 | 1.91 | 6.44 |
| Total Debt / Equity (X) | 0.44 | 0.51 | 0.65 | 5.86 | 21.74 |
| Asset Turnover Ratio (%) | 0.94 | 1.56 | 1.76 | 2.38 | 1.43 |
| Current Ratio (X) | 1.56 | 1.60 | 1.99 | 1.16 | 1.21 |
| Quick Ratio (X) | 1.23 | 1.15 | 1.50 | 0.95 | 0.85 |
| Inventory Turnover Ratio (X) | 3.85 | 5.84 | 0.00 | 10.03 | 4.90 |
| Interest Coverage Ratio (X) | 1.71 | 1.72 | 2.46 | 3.34 | 1.18 |
| Interest Coverage Ratio (Post Tax) (X) | 1.48 | 1.54 | 1.95 | 2.73 | 1.07 |
| Enterprise Value (Cr.) | 51.18 | 28.22 | 25.24 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | 0.40 | 0.17 | 0.25 | 0.00 | 0.00 |
| EV / EBITDA (X) | 14.85 | 8.22 | 10.74 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 0.27 | 0.13 | 0.15 | 0.00 | 0.00 |
| Price / BV (X) | 0.89 | 0.60 | 0.61 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 0.27 | 0.13 | 0.15 | 0.00 | 0.00 |
| EarningsYield | 0.02 | 0.04 | 0.06 | 0.00 | 0.00 |
After reviewing the key financial ratios for Dipna Pharmachem Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.41. This value is below the healthy minimum of 5. It has decreased from 0.45 (Mar 24) to 0.41, marking a decrease of 0.04.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.41. This value is below the healthy minimum of 5. It has decreased from 0.45 (Mar 24) to 0.41, marking a decrease of 0.04.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.40. This value is below the healthy minimum of 3. It has decreased from 0.45 (Mar 24) to 0.40, marking a decrease of 0.05.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 16.01. It has increased from 15.60 (Mar 24) to 16.01, marking an increase of 0.41.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 16.01. It has increased from 15.60 (Mar 24) to 16.01, marking an increase of 0.41.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 51.95. It has decreased from 68.34 (Mar 24) to 51.95, marking a decrease of 16.39.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 2. There is no change compared to the previous period (Mar 24) which recorded 1.43.
- For PBIT / Share (Rs.), as of Mar 25, the value is 1.43. This value is within the healthy range. It has increased from 1.42 (Mar 24) to 1.43, marking an increase of 0.01.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.59. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.59.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.40. This value is below the healthy minimum of 2. It has decreased from 0.45 (Mar 24) to 0.40, marking a decrease of 0.05.
- For PBDIT Margin (%), as of Mar 25, the value is 2.75. This value is below the healthy minimum of 10. It has increased from 2.08 (Mar 24) to 2.75, marking an increase of 0.67.
- For PBIT Margin (%), as of Mar 25, the value is 2.75. This value is below the healthy minimum of 10. It has increased from 2.07 (Mar 24) to 2.75, marking an increase of 0.68.
- For PBT Margin (%), as of Mar 25, the value is 1.13. This value is below the healthy minimum of 10. It has increased from 0.86 (Mar 24) to 1.13, marking an increase of 0.27.
- For Net Profit Margin (%), as of Mar 25, the value is 0.77. This value is below the healthy minimum of 5. It has increased from 0.66 (Mar 24) to 0.77, marking an increase of 0.11.
- For Return on Networth / Equity (%), as of Mar 25, the value is 2.53. This value is below the healthy minimum of 15. It has decreased from 2.89 (Mar 24) to 2.53, marking a decrease of 0.36.
- For Return on Capital Employeed (%), as of Mar 25, the value is 7.25. This value is below the healthy minimum of 10. It has increased from 6.82 (Mar 24) to 7.25, marking an increase of 0.43.
- For Return On Assets (%), as of Mar 25, the value is 0.73. This value is below the healthy minimum of 5. It has decreased from 0.81 (Mar 24) to 0.73, marking a decrease of 0.08.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.23. This value is within the healthy range. It has decreased from 0.33 (Mar 24) to 0.23, marking a decrease of 0.10.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.44. This value is within the healthy range. It has decreased from 0.51 (Mar 24) to 0.44, marking a decrease of 0.07.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.94. It has decreased from 1.56 (Mar 24) to 0.94, marking a decrease of 0.62.
- For Current Ratio (X), as of Mar 25, the value is 1.56. This value is within the healthy range. It has decreased from 1.60 (Mar 24) to 1.56, marking a decrease of 0.04.
- For Quick Ratio (X), as of Mar 25, the value is 1.23. This value is within the healthy range. It has increased from 1.15 (Mar 24) to 1.23, marking an increase of 0.08.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.85. This value is below the healthy minimum of 4. It has decreased from 5.84 (Mar 24) to 3.85, marking a decrease of 1.99.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1.71. This value is below the healthy minimum of 3. It has decreased from 1.72 (Mar 24) to 1.71, marking a decrease of 0.01.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.48. This value is below the healthy minimum of 3. It has decreased from 1.54 (Mar 24) to 1.48, marking a decrease of 0.06.
- For Enterprise Value (Cr.), as of Mar 25, the value is 51.18. It has increased from 28.22 (Mar 24) to 51.18, marking an increase of 22.96.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.40. This value is below the healthy minimum of 1. It has increased from 0.17 (Mar 24) to 0.40, marking an increase of 0.23.
- For EV / EBITDA (X), as of Mar 25, the value is 14.85. This value is within the healthy range. It has increased from 8.22 (Mar 24) to 14.85, marking an increase of 6.63.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.27. This value is below the healthy minimum of 1. It has increased from 0.13 (Mar 24) to 0.27, marking an increase of 0.14.
- For Price / BV (X), as of Mar 25, the value is 0.89. This value is below the healthy minimum of 1. It has increased from 0.60 (Mar 24) to 0.89, marking an increase of 0.29.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.27. This value is below the healthy minimum of 1. It has increased from 0.13 (Mar 24) to 0.27, marking an increase of 0.14.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 24) to 0.02, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dipna Pharmachem Ltd:
- Net Profit Margin: 0.77%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 7.25% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 2.53% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.48
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.23
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 21.7 (Industry average Stock P/E: 53.52)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.44
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.77%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | A/211, Siddhi Vinayak Complex, Ahmedabad Gujarat 380055 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Keyur Dipakkumar Shah | Managing Director |
| Ms. Dipna Keyur Shah | Non Executive Director |
| Mr. Nirav Soni | Non Executive Director |
| Mr. Nandish Shaileshbhai Jani | Independent Director |
| Mr. Parin Bhavsar | Independent Director |
FAQ
What is the intrinsic value of Dipna Pharmachem Ltd?
Dipna Pharmachem Ltd's intrinsic value (as of 01 January 2026) is ₹11.06 which is 34.56% lower the current market price of ₹16.90, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹44.4 Cr. market cap, FY2025-2026 high/low of ₹26.3/11.4, reserves of ₹35 Cr, and liabilities of ₹177 Cr.
What is the Market Cap of Dipna Pharmachem Ltd?
The Market Cap of Dipna Pharmachem Ltd is 44.4 Cr..
What is the current Stock Price of Dipna Pharmachem Ltd as on 01 January 2026?
The current stock price of Dipna Pharmachem Ltd as on 01 January 2026 is ₹16.9.
What is the High / Low of Dipna Pharmachem Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Dipna Pharmachem Ltd stocks is ₹26.3/11.4.
What is the Stock P/E of Dipna Pharmachem Ltd?
The Stock P/E of Dipna Pharmachem Ltd is 21.7.
What is the Book Value of Dipna Pharmachem Ltd?
The Book Value of Dipna Pharmachem Ltd is 24.5.
What is the Dividend Yield of Dipna Pharmachem Ltd?
The Dividend Yield of Dipna Pharmachem Ltd is 0.00 %.
What is the ROCE of Dipna Pharmachem Ltd?
The ROCE of Dipna Pharmachem Ltd is 6.64 %.
What is the ROE of Dipna Pharmachem Ltd?
The ROE of Dipna Pharmachem Ltd is 2.55 %.
What is the Face Value of Dipna Pharmachem Ltd?
The Face Value of Dipna Pharmachem Ltd is 10.0.